〔Abstract〕 Objective To study the clinical effect of Dachengqi Decoction Reyanbao combined with Xuebijing in the treatment of patients with sepsis (stasis internal resistance syndrome) and the impact on procalcitonin (PCT) and interleukin-6 (IL–6). Methods A total of 100 patients with sepsis (internal resistance to blood stasis) who were admitted to the Third People's Hospital of Fujian University of Traditional Chinese Medicine from March 2019 to March 2021 were selected as the research objects, and were divided into the control group and observation group using by random number table method. The control group (50 cases, 3 cases of shedding) were given conventional therapy, and the observation group (50 cases, 2 cases of shedding) were given the treatment of Dachengqi Decoction Reyanbao combined with Xuebijing on the basis of the control group. The clinical effect on the two groups of patients and inflammatory factor indicators (PCT, IL-6) were observed and analyzed. Results The total effective rate of treatment in the observation group was 85.42%, which was higher than 65.96% in the control group. The difference was statistically significant (P < 0.05); The comparison of PCT and IL-6 between the two groups before treatment was not statistically significant (P > 0.05). After treatment, the PCT and IL-6 levels of the observation group were lower than those of the control group, and the differences were statistically significant (P < 0.05). Conclusion In the clinical treatment of patients with sepsis (stasis toxin internal resistance), administering Dachengqi Decoction reyanbao external application combined with Xuebijing treatment can improve the total effective rate of treatment, enhance the anti-inflammatory effect, and make the levels of inflammatory factors such as PCT and IL–6 are significantly reduced, reducing the severity of the disease, and better improving the clinical symptoms of patients.